"With a Phase 2a asset in HSV and an EBV program approaching clinical readiness, Innovative Molecules is uniquely positioned as a leading developer of next-generation therapies targeting herpesviruses ...

Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has been dosed in its ...

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of ...

Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patie ...

If the US FDA approves it, aglatimagene immunotherapy may become the first new therapy for men with localized prostate cancer in the past 2 decades.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, ...

Last fall Alexa started seeing a man she met on a dating app. He asked her to get tested for sexually transmitted infections before they began having sex. The first thing she noticed on her screening ...